Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07489768Not Yet Recruiting

GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring

Role: collaborator

NCT07466602Recruiting

cfDNA Methylation for Liver Cancer Recurrence Detection

Role: lead

NCT06564363Unknown

The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma

Role: lead

NCT05680077Completed

KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)

Role: lead

NCT05685524Unknown

Clinical Study of Pan-cancer DNA Methylation Test in Plasma

Role: lead

NCT05668793Unknown

GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method)

Role: lead

All 6 trials loaded